RxDoctor Payments DataLook up a doctor →

Donald Yakel, MD

Interventional Cardiology · Springfield, ILNPI 1568559359

Payments from drug & device makers

$503,310in general payments, 2019–2025

Across 441 payments — averaging $1141.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$346K
  • Janssen Research & Development, LLC$103K
  • Abbott$27K
  • Medtronic$13K
  • Edwards Lifesciences$3K
  • Cordis US CORP.$3K
  • plus $8K from 29 others

What the payments were for

  • Consulting fees$9,50017%
  • Speaking & faculty fees$7,50014%
  • Travel & lodging$23,05442%
  • Food & beverage$14,37026%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$503,310 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$209,495
Medicare patients
645
Services billed
1,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$257,688
EntrestoSacubitril/Valsartan35$44,547
XareltoRivaroxaban35$37,684
BrilintaTicagrelor38$35,319
JardianceEmpagliflozin22$31,917
ClopidogrelClopidogrel Bisulfate588$6,555
Metoprolol Succinate462$4,926
Atorvastatin Calcium286$2,429
Isosorbide Mononitrate ErIsosorbide Mononitrate182$1,770
Isosorbide Dinitrate21$1,685
Carvedilol181$1,678
Nitroglycerin95$1,625
Amiodarone Hcl38$1,288
Losartan Potassium166$1,189
Lisinopril162$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$257,688235 claims
NovartisEntresto$345,988$44,54735 claims
Johnson & JohnsonXarelto$64$37,68435 claims
AstraZenecaBrilinta$14$35,31938 claims
Boehringer IngelheimJardiance$58$31,91722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →